Here, we demonstrate that 24 h after the application of the anti-EGFR ILs-dox, a significant concentration of doxorubicin was detectable in the glioblastoma tissue, while anti-EGFR ILs-dox were not able to cross the BBB at clinically relevant levels as the levels found in the CSF were negligible, although high levels of doxorubicin had been detected meanwhile in the plasma. This evidence concerns the gene EGFR and glioblastoma.